

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 5/10, A61K 37/02	A1	(11) International Publication Number: WO 91/16339 (43) International Publication Date: 31 October 1991 (31.10.91)
<p>(21) International Application Number: PCT/US91/02519</p> <p>(22) International Filing Date: 12 April 1991 (12.04.91)</p> <p>(30) Priority data: 510,274 14 April 1990 (14.04.90) US</p> <p>(71) Applicants: NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. [US/US]; 750 Washington Street, Boston, MA 02111 (US). TUFTS UNIVERSITY SCHOOL OF MEDICINE [US/US]; 136 Harrison Avenue, Boston, MA 02111 (US).</p> <p>(72) Inventors: BACHOVCHIN, William, W. ; 71 Warwick Road, Melrose, MA 02176 (US). PLAUT, Andrew, G. ; New England Medical Center, 750 Washington Street, Boston, MA 02111 (US). FLENTKE, George, R. ; Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111 (US).</p>		<p>(74) Agent: CLARK, Paul, T.; Fish & Richardson, 225 Franklin Street, Boston, MA 02110 (US).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p>Published With international search report.</p>
<p>(54) Title: INHIBITORS OF DIPEPTIDYL-AMINOPEPTIDASE TYPE IV</p> <p>(57) Abstract</p> <p>Inhibitors of Dipeptidyl-Aminopeptidase Type IV having the following general formula: X-Pro-Y-boroPro, where X and Y are chosen from any amino acid (including proline).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

WO 91/16339

Inhibitors of Dipeptidyl-Aminopeptidase Type IV

Background of the Invention

This invention relates to inhibitors of the amino-peptidase activity of dipeptidyl amino peptidase type IV (DP

5 IV). DP IV is a serine protease present in many microbes, mammalian cells and tissues, for example, renal tubule cells, intestinal epithelium, and blood plasma. It is also present on the surface of CD-4+ and some CD-8+ T-cells, and
10 in low amounts in the central nervous system. It is thought to be involved in the regulation of the immune response; occurrence of DP IV on a cell surface is associated with the ability of cells to produce interleukin 2 (IL-2). DP IV is also referred to as DAP IV or DPP IV; it is assigned EC
15 number 3.4.14.5.

Three different inhibitors of DP IV are known. One of these is a suicide inhibitor: N-Ala-Pro-O-(nitrobenzyl-)hydroxylamine. (The standard three letter amino acid codes are used in this application; O represents oxygen.) Another
20 is a competitive inhibitor: e-(4-nitro)benzoxycarbonyl-Lys-Pro. The third is a polyclonal rabbit anti-porcine kidney DP IV immunoglobulin.

Summary of the Invention

The enzymatic activity of DP IV involves cleaving of
25 a dipeptide from the free amino terminus of a polypeptide. DP IV has a preference for cleaving after a proline, i.e., a proline in the penultimate position from the amino terminus. A free amino terminus is required; thus, DP IV is a postproline cleaving enzyme with a specificity for removing
30 an N-terminal W-Pro dipeptide from a polypeptide (where W can be any amino acid, including proline). DP IV

WO 91/16339

PCT/US91/02519

- 2 -

also will remove a W'-Ala dipeptide from an amino terminus of a polypeptide when W' is an amino acid with a bulky side group, e.g., tyrosine.

This invention concerns provision of potent inhibitors of the enzymatic activity of DP IV. Generally, an α -amino boronic acid analog of proline (boroPro is used to designate one such analog which has the carboxyl group of proline replaced with a $B(OH)_2$ group, where $(OH)_2$ represents two hydrogen groups and B represents boron) is bonded to an amino acid to form a dipeptide with boroPro as the C-terminal residue. These dipeptide prolyl- boronic acids are potent and highly specific inhibitors of DP IV activity and have K_i values in the nanomolar range.

Dipeptides having the boroPro moiety are unstable; thus, we have designed inhibitors having at least two other amino acids. Generally, the structure of these inhibitors is X-Pro-Y-boroPro where X and Y are chosen from any amino acid (including proline). This tetrapeptide may be lengthened at its N-terminus by addition of one or more dipeptides, each dipeptide having the general formula Z-Pro or Z-ala, where each Z independently is any amino acid (including proline). This general structure is defined in more detail below. These inhibitors function as inhibitors of DP IV because each dipeptide portion is a substrate for DP IV and the final product of the reaction of an inhibitor with DP IV is the dipeptide inhibitor Y-boroPro. The amino terminus of these inhibitors must not be blocked or they lose their inhibitory capacity for DP IV, since DP IV cannot cleave a dipeptide from a blocked N-terminal polypeptide.

Thus, in a first aspect, the invention features an inhibitory compound having the structure: Group I - Group II. Group I has the structure:

PCT/US91/02519

- 3 -



15



25

30


where G5 and G6 can be NH, H, or C1 - 3 alkyl or alkenyl with one or more carbons substituted with a nitrogen. G1 bears a charge, and G1 and Group II do not form a covalently

WO 91/16339


PCT/US91/02519

- 4 -



bonded ring structure at pH 7.0. Group I may also have the structure:



- where one or two of the a, b, c, d, e, and f group is N, and the rest are C, and each S1 - S6 independently is H or C1 - C3 alkyl. Group I may also include a five membered unsaturated ring having two nitrogen atoms, e.g., an imidazole ring. Group II has the structure:



- 15 where T is a group of the formula:



- 25 where G is either H, fluorine (F) or an alkyl group containing 1 to 20 carbon atoms and optional heteroatoms

WO 91/16339



PCT/US91/02519

- 5 -

which can be N, S (sulfur), or O; or a phosphonate group of the formula:



where each J, independently, is O-alkyl, N-alkyl, or alkyl. Each O-alkyl, N-alkyl or alkyl includes 1 - 20 carbon atoms and, optionally, heteroatoms which can be N, S, or O. T is generally able to form a complex with the catalytic site of a DP IV.



and each R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈, separately is a group which does not significantly interfere with site specific recognition of the inhibitory compound by DP IV, and allows a complex to be formed with DP IV.

In preferred embodiments, T is a boronate group, a phosphonate group or a trifluoroalkyl ketone group; each R₁-R₈ is H; each R₁ and R₂ is H, and each Y is the CH₂-CH₂; each R is independently chosen from the R group of proline and alanine; the inhibitory compound has a binding or dissociation constant to DP IV of at least 10⁻⁹M, 10⁻⁸M or even 10⁻⁷M; the inhibitory compound is admixed with a pharmaceutically acceptable carrier substance; and each D₁

WO 91/16339

PCT/US91/02519

- 6 -

and D2 is, independently, F, or D1 and D2 together are a ring containing 1 to 20 carbon atoms, and optionally heteroatoms which can be N, S, or O.

In a second aspect, the invention features a method
5 for inhibiting the enzymatic activity of DP IV in a
bacterium or mammal. The method includes administering to
the mammal an effective amount of an inhibitory compound
described above. Most preferably, the amount of compound
administered is between 1 - 500 mg/kilogram of animal
10 treated/day.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments, and from the claims.

Description of the Preferred Embodiments

15 The drawings will first be briefly described.

Drawings

Figure 1 is a diagrammatic representation of the synthesis of a boro proline compound; and

20 Figure 2 is a diagrammatic representation of several embodiments of the invention.

Structure

The inhibitory compounds of the invention have the general structure recited in the Summary of the Invention above. Examples of preferred structures are those referred
25 to as preferred embodiments above.

The structure of the inhibitory compounds is such that at least a portion of the amino acid sequence near the cleavage site of a DP IV substrate is duplicated, or nearly duplicated. This duplication is in part responsible for the
30 ability of the inhibitory compounds to inhibit DP IV, by a mechanism thought to involve competitive inhibition between a DP IV inhibitory compound or DP IV cleavage product of the inhibitory compound, and the actual DP IV substrate.

WO 91/16339


PCT/US91/02519

- 7 -

The choice of amino acid sequence affects the inhibitory activity of the inhibitory compound, and its specificity. Peptide fragments can be synthesized and then tested to determine their efficacy as inhibitors, using standard techniques. Specificity is determined in a similar fashion, by testing the inhibitory effect of a particular inhibitory compound on the enzyme activity. The inhibitory compounds preferably inhibit the enzymatic activity of DP IV and do not inhibit enzymes necessary for normal cell functions.

The inhibitory compounds include a group (T) which causes the inhibitory compound to complex with DP IV, not only in a competitive fashion, but in a chemically reactive manner to form a strong bond between the inhibitory compound and DP IV. This group thus acts to bind the inhibitory compound to DP IV, and increases the inhibitory binding constant (K_i) of the inhibitory compound. Examples of such groups include boronates, fluoroalkyl ketones and phosphoramidates (of the formulae given in the Summary above). These groups are covalently bonded to the prolyl residue of the compound, as in the above formula.

The proline or proline analog, represented by



above, is chosen so that it mimics the structure of proline recognized by the active site of DP IV. It can be modified by providing R1 and R2 groups which do not interfere significantly with this recognition, and thus do not significantly affect the K_i of the compound. Thus, one or more hydroxyl groups can be substituted to form hydroxy-

WO 91/16339

PCT/US91/02519

- 8 -

proline, and methyl or sugar moieties may be linked to these groups. One skilled in the art will recognize that these groups are not critical in this invention and that a large choice of substituents are acceptable for R1 and R2.

5 Synthesis

Synthesis of boroProline

Referring to Figure 1, the starting compound I is prepared essentially by the procedure of Matteson et al., 3 Organometallics 1284, 1984, except that a pinacol ester is substituted for the pinanediol ester. Similar compounds such as boropiperic acid and 2-azetidine boronic acid can be prepared by making the appropriate selection of starting material to yield the pentyl and propyl analogs of compound I. Further, Cl can be substituted for Br in the formula, and other diol protecting groups can be substituted for pinacol in the formula, e.g., 2,3-butanediol and alpha-pinanediol.

Compound II is prepared by reacting compound I with $[(CH_3)_3Si]_2N-Li^+$. In this reaction hexamethyldisilazane is dissolved in tetrahydrofuran and an equivalent of n-butyllithium added at $-78^\circ C$. After warming to room temperature ($20^\circ C$) and cooling to $-78^\circ C$ an equivalent of compound I is added in tetrahydrofuran. The mixture is allowed to slowly come to room temperature and to stir overnight. The alpha-bis[trimethylsilane]-protected amine is isolated by evaporating solvent and adding hexane under anhydrous conditions. Insoluble residue is removed by filtration under a nitrogen blanket, yielding a hexane solution of compound II.

30 Compound III, the N-trimethylsilyl protected form of boroProline is obtained by the thermal cyclization of compound II during the distillation process in which

WO 91/16339

PCT/US91/02519

- 9 -

compound II is heated to 100-150°C and distillate is collected which boils 66-62°C at 0.06-0.10 mm pressure.

Compound IV, boroProline-pinacol hydrogen chloride, is obtained by treatment of compound III with HCl:dioxane.

- 5 Excess HCl and by-products are removed by trituration with ether. The final product is obtained in a high degree of purity by recrystallization from ethyl acetate.

- The boroProline esters can also be obtained by treatment of the reaction mixture obtained in the preparation of compound II with anhydrous acid to yield 1-amino-4-bromobutyl boronate pinacol as a salt. Cyclization occurs after neutralizing the salt with base and heating the reaction.

- 15 Example 1: Preparation of boroProline-pinacol
(H-boroPro-pinacol)

- The intermediate, 4-Bromo-1-chlorobutyl boronate pinacol, was prepared by the method in Matteson et al., Organometallics, (3): 1284-1288 (1984), except that conditions were modified for large scale preparations and the pinacol was substituted for the pinanedoil protecting group.

- 25 3-bromopropyl boronate pinacol was prepared by hydrogenboration of allyl bromide (173 ml, 2.00 moles) with catechol borane (240 ml, 2.00 moles). Catechol borane was added to allyl bromide and the reaction heated for 4 hours at 100°C under a nitrogen atmosphere. The product, 3-bromopropyl boronate catechol (bp 95-102°C, 0.25 mm), was isolated in a yield of 49% by distillation. The catechol ester (124 g, 0.52 moles) was transesterified with pinacol 30 (61.5 g, 0.52 moles) by mixing the component in 50 ml of THF and allowing them to stir for 0.5 hours at 0°C and 0.5 hours at room temperature. Solvent was removed by evaporation and 250 ml of hexane added. Catechol was removed as a

WO 91/16339

PCT/US91/02519

- 10 -

crystalline solid. Quantitative removal was achieved by successive dilution to 500 ml and to 1000 ml with hexane and removing crystals at each dilution. Hexane was evaporated and the product distilled to yield 177 g (bp 60 - 64°C, 0.35 mm).

5 4-Bromo-1-chlorobutyl boronate pinacol was prepared by homologation of the corresponding propyl boronate. Methylene chloride (50.54 ml, 0.713 moles) was dissolved in 500 ml of THF, 1.54 N n-butyllithium in hexane (480 ml, 10 0.780 moles) was slowly added at -100°C. 3-Bromopropyl boronate pinacol (178 g, 0.713 moles) was dissolved in 500 ml of THF, cooled to the freezing point of the solution, and added to the reaction mixture. Zinc chloride (54.4 g, 0.392 15 moles) was dissolved in 250 ml of THF, cooled to 0°C, and added to the reaction mixture in several portions. The reaction was allowed to slowly warm to room temperature and to stir overnight. Solvent was evaporated and the residue dissolved in hexane (1 liter) and washed with water (1 20 liter). Insoluble material was discarded. After drying over anhydrous magnesium sulfate and filtering, solvent was evaporated. The product was distilled to yield 147 g (bp 110 - 112°C, 0.200 mm).

N-Trimethylsilyl-boroProline pinacol was prepared first by dissolving hexamethyldisilazane (20.0 g, 80.0 25 mmoles) in 30 ml of THF, cooling the solution to -78°C, and adding 1.62 N n-butyllithium in hexane (49.4 ml, 80.0 mmoles). The solution was allowed to slowly warm to room temperature. It was recooled to -78°C and 4-bromo-1-chlorobutyl boronate pinacol (23.9 g, 80.0 mmoles) added in 30 20 ml of THF. The mixture was allowed to slowly warm to room temperature and to stir overnight. Solvent was removed by evaporation and dry hexane (400 ml) added to yield a precipitant which was removed by filtration under an

WO 91/16339

PCT/US91/02519

- 11 -

nitrogen atmosphere. The filtrate was evaporated and the residue distilled, yielding 19.4 g of the desired product (bp 60 - 62°C, 0.1 - 0.06 mm).

H-boroProline-pinacol.HCl was prepared by cooling N-trimethylsilyl-boroProline-pinacol (16.0 g, 61.7 mmoles) to -78°C and adding 4 N HCl:dioxane 46 ml, 185 mmoles). The mixture was stirred 30 minutes at -78°C and 1 hour at room temperature. Solvent was evaporated and the residue triturated with ether to yield a solid. The crude product was dissolved in chloroform and insoluble material removed by filtration. The solution was evaporated and the product crystallized from ethyl acetate to yield 11.1 g of the desired product (mp 156.5 - 157°C).

Synthesis of boroProline Peptides

General methods of coupling of N-protected peptides and amino acids with suitable side-chain protecting groups to H-boroProline-pinacol are applicable. When needed, side-chain protecting and N-terminal protecting groups can be removed by treatment with anhydrous HCl, HBr, trifluoroacetic acid, or by catalytic hydrogenation. These procedures are known to those skilled in the art of peptide synthesis.

The mixed anhydride procedure of Anderson et al., J. Am. Chem. Soc., **89**:5012 (1984) is preferred for peptide coupling. Referring again to Figure 1, the mixed anhydride of an N-protected amino acid or a peptide varying in length from a dipeptide to tetrapeptide is prepared by dissolving the peptide in tetrahydrofuran and adding one equivalent of N-methylmorpholine. The solution is cooled to -20°C and an equivalent of isobutyl chloroformate is added. After 5 minutes, this mixture and one equivalent of triethylamine (or other sterically hindered base) are added to a solution

WO 91/16339

PCT/US91/02519

- 12 -

of H-boroPro-pinacol dissolved in either cold chloroform or tetrahydrofuran.

The reaction mixture is routinely stirred for one hour at -20°C and 1 - 2 hours at room temperature (20°C).

- 5 Solvent is removed by evaporation, and the residue is dissolved in ethyl acetate. The organic solution is washed with 0.20 N hydrochloric acid, 5% aqueous sodium bicarbonate, and saturated aqueous sodium chloride. The organic phase is dried over anhydrous sodium sulfate, 10 filtered, and evaporated. Products are purified by either silica gel chromatography or gel permeation chromatography using Sephadex[™] LH-20 and methanol as a solvent.

- Previous studies have shown that the pinacol protecting group can be removed in situ by preincubation in 15 phosphate buffer prior to running biological experiments; Kettner et al., J. Biol. Chem. 259: 15106-15114 (1984). Several other methods are also applicable for removing pinacol groups from peptides including boroProline and characterizing the final product. First, the peptide can be 20 treated with diethanolamine to yield the corresponding diethanolamine boronic acid ester, which can be readily hydrolyzed by treatment with aqueous acid or a sulfonic acid substituted polystyrene resin as described in Kettner et al., id. Both pinacol and pinanediol protecting groups 25 can be removed by treating with BCl_3 in methylene chloride as described by Kinder et al., J. Med. Chem., 28: 1917. Finally, the free boronic acid can be converted to the difluoroboron derivative ($-\text{BF}_2$) by treatment with aqueous HF as described by Kinder et al., id.

- 30 Similarly, different ester groups can be introduced by reacting the free boronic acid with various di-hydroxy compounds (for example, those containing heteroatoms such as S or N) in an inert solvent.

WO 91/16339

PCT/US91/02519

- 13 -

Example 2: H-Ala-boroPro

Boc-Ala-boroPro was prepared by mixed anhydride coupling of the N-Boc-protected alanine and H-boroPro prepared as described above. H-Ala-boroPro was prepared by
5 removal of the Boc protecting group at 0°C in 3.5 molar excess of 4 N HCl-dioxane. The coupling and deblocking reactions were performed by standard chemical reaction. Ala-boroPro has a K_i for DP IV of $-1 \times 10^{-9}M$. Boc-blocked
10 Ala-boroPro has no affinity for DP IV.

The two diastereomers of H-Ala-boroPro-pinacol can be partially separated by silica gel chromatography with 20% methanol in ethyl acetate as eluant. The early fraction appears by NMR analysis to be 95% enriched in one isomer. Because this fraction has more inhibitory power against DP
15 IV than later fractions (at equal concentrations) it is probably enriched in the L-boroPro isomer.

One significant drawback with H-Ala-boroPro as an inhibitor for DP IV is that it decomposes in aqueous solution at neutral pH and room temperature (20 - 25°C) with
20 a half-life of around 0.5 hour. Many dipeptide derivatives with a free N terminal amino group and a functional group (such as a difluoromethyl ketone) on the C-terminus are similarly unstable due to intramolecular reaction. A six member ring is formed between the amino and C-terminal
25 functional groups and undergoes subsequent further reaction, such as hydrolysis. DP IV bound inhibitor is more stable, consistent with the hypothesis that decomposition is due to an intramolecular reaction.

H-Pro-boroPro is more stable than H-Ala-boroPro.
30 The K_i of H-Pro-boroPro for DP IV is about $1 \times 10^{-8}M$, and it decomposes in aqueous solution at room temperature (20-25°C) with a half life of about 1.5 hours. Although the

- 14 -

affinity of H-Pro-boroPro is about 10-fold less than that of H-Ala-boroPro, the increased stability is advantageous.

Because of the relatively short half life of the above dipeptides inhibitory compounds of the invention are formed as tetrapeptides or longer peptides as shown in the general formula above. These inhibitory compounds are substrates for DP IV yielding the dipeptide inhibitor W-boroPro. These tetrapeptide boronic acids are generally stable and can be administered by any standard procedure to act as a substrate for DP IV and then as a source of a potent DP IV inhibitor. The advantages of such tetrapeptides is that inhibitor is released only in the vicinity of active DP IV. These tetrapeptide boronic acids can be made by the method of mixed anhydride coupling by one of ordinary skill in the art, e.g., Mattason, Organometallics 3:1284 to 1288, 1984.

Test Systems

The following are examples of systems by which the inhibitory activity of the above described inhibitory compounds can be tested on DP IV. As an example H-Ala-boroPro is used to test each of these systems. Inhibitory compounds can be tested by simply substituting them for H-Ala-boroPro.

DP IV is purified from pig kidney cortex by the method of Barth et al., Acta Biol. Med. Germ. (1974) 32:157, and Wolf et al., Acta Biol. Med. Germ. (1978) 37:409, and from human placenta by the method of Puschel et al., E. Eur. J. Biochem. (1982) 126:359. H-Ala-boroPro inhibits both enzymes with a K_i of $-1.0 \times 10^{-9} M$.

WO 91/16339

PCT/US91/02519

- 15 -

Human Peripheral Blood Mononuclear Cells

H-Ala-boroPro was tested for its influence on PHA-induced proliferation of human peripheral blood mononuclear cells. Human peripheral blood mono-nuclear cells were
5 obtained from healthy human donors by Ficoll-Hypaque density gradient centrifugation. The cells are washed three times in RPMI 1640 medium and resuspended to a concentration of a 1×10^6 in RPMI. 10% human serum was used as necessary.

The proliferative response of lymphocytes was
10 measured using ^3H -Thymidine incorporation. MNC cells [Ford, W.L. in Handbook of Experimental Immunology edit. by: D.M. Weir. Blackwell Scientific Publications, Oxford, 1978. p. 23.6] (5×10^3) were distributed into wells of round-bottom microtitre plates (Nunc) and incubated in the presence or
15 absence of various dilutions of antigen, mitogen, lymphokine or other agent of interest. Cells were cultured in a atmosphere of 5% CO_2 in air for 72 hours after which ^3H -Thymidine (0.5 $\mu\text{Ci}/\text{well}$; 2.0 Ci/mM sp.act., New England Nuclear) was added 6 hours before termination of culture.
20 The cells were harvested with a multiple automatic harvester, and ^3H -thymidine incorporation assessed by liquid scintillation counting. ^3H thymidine incorporation was determined relative to control values in the absence of inhibitor. Inhibitor was added to give a final
25 concentration of $1 \times 10^{-4}\text{M}$, but lower concentrations can be used.

HIV gene replication

We examined the effect of H-Ala-boroPro on HIV-1 replication in vitro. The rationale for these experiments
30 comes from the reported connection between T-cell activation, IL-2 production, and HIV replication and expression of HIV proteins. For example, inductive signals

WO 91/16339

PCT/US91/02519

- 16 -

associated with HIV replication include mitogens, antigens, lymphokines, and transcriptions factors such as NF-kB, all of which have been shown to be associated with induction of IL-2 production, T-cell activation, or both.

5 Cell lines used in the present studies include A3.5 cells (a monocyte cell line which is CD4+, HLA-DR+, and CD3-) and peripheral blood mononuclear cells (PBMC). The A3.5 cells grow continuously in culture without exogenous growth factors. PBMC cells require IL-2 for propagation in
10 vitro. Cells were infected with HIV-1IIIIB at a multiplicity of infection (moi) of 5×10^{-4} tissue culture infectious dose 50 (TCID50)/cell for both the A3.5 cells and the PMBC cells. Dilutions of inhibitor were made in RPMI-1640 and subsequently passed through a 0.22 um filter. At the start
15 of each experiment, 1×10^6 cells/well, in 24-2311 plates, were infected with HIV-1IIIIB at the moi indicated above. Inhibitor was added simultaneously at the appropriate dilutions. All cultures were maintained at 5% CO₂ and 37°C in RPMI-1640 supplemented with penicillin, streptomycin, L-
20 glutamine, hepes buffer, and 20% heat-inactivated fetal calf serum. Cell counts and viability were determined by trypan blue exclusion. Culture supernatants were harvested and assayed for HIV-1 p24 antigen by ELISA (NEN-DuPont, Boston, MA). Fresh media and inhibitor were added on each day. For
25 PBMC cultures, cells were collected from HIV-1 seronegative donors and stimulated with PHA-P (Difco, Detroit, MI; 10 µg/ml) and 10% IL-2 (Electronnucleonics, Silver Spring, MD) 3 days prior to infection with HIV-1. PBMC cultures for all experiments included uninfected and infected cells without
30 inhibitor, uninfected cells with inhibitor at the various concentrations, and infected cells in the presence of 1 um zidovudine (azidothymidine, AZT).

WO 91/16339

- 17 -

With A3.5 cells H-Ala-boroPro suppresses HIV below detectable levels in a manner similar to the anti-HIV effect of AZT at 1 μ m. Similar results were observed with the PBMC cells. Thus, inhibitors of this invention have an anti HIV effect. Cell viability assays show that these inhibitors are not cytotoxic even at relatively high concentration (10-3 M for A3.5 cells).

Determination of DP IV Activities in Biological

Samples

10 The ability to determine DP IV activities associated with cells and tissues is highly desirable. For example, it will permit correlations to be made between level of inhibition of DP IV and the magnitude of the observed biological affect, e.g., on cell proliferation, and IL-2
15 production. Such correlation is helpful in establishing whether or not the biological affect is due to inhibition of DP IV. We have found that such determinations can be reproducibly and reliably made using the readily available
20 X-Pro-7-amino-4-trifluoromethyl coumarins (AFC). The AFC substrates are fluorescent and thus provide greater sensitivity. DP IV activity is measured as release of p-nitroanilide spectrophotometrically at 410nM, or using X-Pro-AFC derivatives and measuring fluorescence at 505nM.
25 Reduction in activity in the presence of inhibitor provides an easy test for inhibitory activity.

Use

The inhibitory compounds can be administered in an effective amount either alone or in combination with a
30 pharmaceutically acceptable carrier or diluent.

The above inhibitory compounds are useful for treatment of a wide variety of disease; for example, an autoimmune disease, the pathogenesis of which is dependent

- 18 -

on T cell activity. DP IV plays a role in such autoimmune disease and inhibition of DP IV activity allows regulation of the progress of the disease. Such diseases include arthritis, rejection of transplanted organs, as well as SLE and AIDS. When administered to mammals (e.g., orally, topically, intramuscularly, intraperitoneally, intravenously, parenterally, nasally or by suppository), the inhibitory compounds of this invention enhance the ability of, e.g., the immune system of the mammal, to fight the disease.

Inhibitors of DP IV can suppress IL-2 production and thus diseases in which the production of IL-2 is altered may be treated by use of these inhibitors. These inhibitors can also delay catabolism of growth hormone releasing factor, and block DPIV activity of amoebae and microbial pathogens to allow an immune system to act more efficiently.

The inhibitory compounds or compositions can be administered alone or in combination with one another, or in combination with other therapeutic agents. The dosage level may be between 1 - 500 mg/kg/day.

Other Embodiments

Other embodiments are within the following claims. For example, other inhibitors can be created which mimic the structure of Ala-boroPro. Examples of such inhibitors are shown in Fig. 2 and include Ala-boroPro. These inhibitors generally have a boroPro group, or its equivalent, described above in the Summary of the Invention, and a positively charged amine group. The inhibitors are designed so that minimal interaction of the amine and boroPro groups occurs, and thus no cyclic structure is formed at pH 7.0. These inhibitors interact and/or bind with DPIV, and thereby reduce the DPIV enzymatic activity toward a normal

WO 91/16339

PCT/US91/02519

- 19 -

substrate. These inhibitors are synthesized by procedures well known to those of ordinary skill in this art.

What is claimed is:

WO 91/16339


PCT/US91/02519

- 20 -

1. An inhibitor compound, having the structure


Group I - Group II

where Group I has the structure:



wherein each R, independently, is chosen from the group consisting of the R groups of an amino acid including proline; each broken line, independently, represents a bond to an H or a bond to one said R group, and each H' represents said bond or a hydrogen; p is an integer between 0 and 4 inclusive;

or Group I has the structure:



where n is between 0 and 3 inclusive,
each G2 and G3 independently is H or C1 - 3 alkyl,
G1 is NH₃, NH - C(=O) - NH₂, or
NH₂

NG4, where G4 is C - G5
G6


where G5 and G6 can be NH, H, or C1 - 3 alkyl or alkenyl with one or more carbons substituted with a nitrogen; provided that G1 bears a charge and G1 and Group II do not form a covalently bonded ring structure at pH 7.0;

or Group I has the structure:


WO 91/16339

PCT/US91/02519


- 21 -




37 where one or two of said a, b, c, d, e, and f is N
 38 and the rest are C, and each S1 - S6 independently is H or
 39 C1 - C3 alkyl; where Group II has the structure:



47 T is a group of the formula:



51 is a hydroxyl group or a group which is capable of being
 52 hydrolysed to a hydroxyl group in aqueous solution at
 53 physiological pH; a group of the formula:



57 where G is either H, F or an alkyl group containing 1 to 20
 58 carbon atoms and optional heteroatoms which can be N, S, or
 59 O; or a phosphonate group of the formula:



WO 91/16339

PCT/US91/02519

- 22 -



65 where each J, independently, is O-alkyl, N-alkyl, or alkyl,
66 each said O-alkyl, N-alkyl or alkyl comprising 1 - 20 carbon
67 atoms and, optionally, heteroatoms which can be N, S, or O;
68 said T being able to form a complex with the catalytic site
69 of a dipeptidyl-aminopeptidase type IV (DP IV) enzyme;



80 and each R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈, separately is a
81 group which does not significantly interfere with site
82 specific recognition of said inhibitory compound by said DP
83 IV, and allows said complex to be formed with said DP IV.

1 2. The compound of claim 1, wherein T is a boronate
2 group.

1 3. The compound of claim 1, wherein T is a
2 phosphonate group or a trifluoroalkyl ketone group.

1 4. The compound of claim 1 wherein each R₁ - R₈ is
2 H.

WO 91/16339

PCT/US91/02519

- 23 -

1 5. The compound of claim 1 or 2 wherein each R1 and
2 R2 are H, and each Y is CH₂ - CH₂.

1 6. The compound of claim 5 wherein each R is
2 independently chosen from the R group of proline and
3 alanine.

1 7. The compound of claim 1, wherein said compound
2 has a binding or dissociation constant to said DP IV of at
3 least 10⁻⁹M.

1 8. The compound of claim 1, wherein said compound
2 has a binding constant to said DP IV of at least 10⁻⁸M.

1 9. The compound of claim 1 admixed within a
2 pharmaceutically acceptable carrier substance.

1 10. The compound of claim 1 wherein, each D1 and D2
2 is, independently, F or D1 and D2 together are a ring
3 containing 1 to about 20 carbon atoms, and optionally
4 heteroatoms which can be N, S, or O.

1 11. A method for inhibiting DP IV in a mammal,
2 comprising administering to said mammal an effective amount
3 of a compound of claim 1.


1 12. The method of claim 11 wherein said amount is 1
2 - 500 mg/kg/day.

WO 91/16339


PCT/US91/02519

1/2


FIG. 1



4-bromo-1-chlorobutyl boronate pinacol



4-bromo-1-[(bistrimethylsilyl) amino] butyl boronate pinacol



1-trimethylsilyl-boroProline pinacol

(IV) boroProline-pinacol-HCL










FIG. 2




$R = H, CH_3$



$n = 1-3$



$R = \text{alkyl } (C_1, C_3), H$
 $n = 1-3$



$n = 2-4$

INTERNATIONAL SEARCH REPORT

International Application PCT/US91/02519

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ¹		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5): C07K 5/10; A61K 37/02		
U.S. CL.: 514/18; 530/330		
II. FIELDS SEARCHED		
Minimum Documentation Searched ²		
Classification System	Classification Symbols	
U.S.	514/18; 530/330	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ³		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁴		
Category ⁵	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P, X	US, A 4,935,493 (BACHOVCHIN ET AL.) 19 June 1990, see entire document.	1-12
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (is specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is considered with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document number of the same patent type</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
20 May 1991		17 JUL 1991
International Searching Authority		Signature of Authorizing Officer
ISA/US		Stephen B. Maebius
		Stephen B. Maebius (vsh)

Form PCT-SA210 (Rev. 10/90)